Skip to main content
. Author manuscript; available in PMC: 2019 Jul 1.
Published in final edited form as: Antiviral Res. 2018 May 16;155:67–75. doi: 10.1016/j.antiviral.2018.05.001

Figure 4. Ex vivo antiviral activity of sunitinib and erlotinib in human primary dendritic cells.

Figure 4.

Cell viability (blue) and dose response of DENV infection (black) to sunitinib (left) and erlotinib (right) measured by alamarBlue assays and luciferase assays, respectively, 72 hours after infection of primary human MDDCs. Data are plotted relative to vehicle control. Shown is a representative experiment with cells from a single donor, out of 3 independent experiments conducted with cells derived from 3 donors, each with 5 biological replicates; shown are means ± SD.